PIRAMAL PHARMA LIMITED (PPLPHARMA): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹246.37 latest close · +40.0% over the last 90 sessions

₹246.37 month-end · +31.6% over 12 months

₹246.37 month-end · +94.6% over 3 years

₹246.37 month-end · +53.0% since Oct '22

52-week range ₹132.30 to ₹250.40 · 1-year volatility 37.4%

How rough has the ride been?

Maximum drawdown-66.3%recovered 2024-08

1-year volatility37.4%annualised

Beta vs sector index1.363-year daily, correlation 0.50

Volume spikes5last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-66.3% (2022-10 peak to 2023-03 low, recovered 2024-08)

-54.6% (2024-11 peak to 2026-03 low, not yet recovered)

Most recent volume spikes

2026-10-30: 9.3x the 50-day median, price +3.5% that day

2026-10-29: 9.2x the 50-day median, price -0.9% that day

2026-10-28: 41x the 50-day median, price +17.1% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE16thflat vs a year ago
Op. margin23rd▲ 3 pts vs a year ago
Revenue growth24th▼ 29 pts vs a year ago
EPS growth1st▼ 96 pts vs a year ago
Debt/equity ↓14th▼ 5 pts vs a year ago
Cash cycle ↓50th▲ 14 pts vs a year ago
P/E ↓2ndflat vs a year ago
12M momentum71st▲ 42 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹246.37
ROCE: 3.0%
Market Cap: ₹32788 cr
Revenue (TTM): ₹9205 cr
P/S: 3.6x
P/B: 4.0x
ROE: -3.8%
Operating Margin: 8.6%
Debt / Equity: 0.7x
Promoter Holding: 34.8%
12M Momentum: 31.6%

52-week range

₹132.30₹250.40

97% of the way from its 52-week low to its high

Price risk

1Y volatility

37.4%

Beta vs sector

1-year daily

1.48

Balance sheet & cash

Interest cover

operating profit ÷ interest

0.7x

Cash from profit, 3Y

operating cash flow ÷ net profit

5.00x

Share count, 1Y

+0.2%

Are profits backed by cash?

2 of 4checks within range2 near a threshold

Other income reliance—Not enough data

Not enough reported data to compute this.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-5 daysWithin range

Debtor days are below the median of the previous three fiscal years by 5 days (89 vs 94). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress13% of fixed assetsWithin range

Capital work-in-progress is 13% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+89 days / 2 yrsNear threshold

Days payable changed by +89 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, FIIs trimmed 19.9 pts; DIIs added 6.6 pts.
The number of shareholders rose from 3.0 lakh to 4.6 lakh (+53%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters35.0%34.8%-0.2 pts

FIIs32.4%12.5%-19.9 pts

DIIs8.0%14.6%+6.6 pts

Public and others24.2%37.6%+13.4 pts

Number of shareholders

4.6 lakhshareholders+53% since Sep '23

Large shift in the Jun '26 quarter: FII + DII −18.7 pp, Public +18.6 pp.
This can be a holder relabelled as Public, a change in the share base, new shares issued or a block deal, so smart money does not count it as buying or selling.

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−13.0%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like PIRAMAL PHARMA LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −24% to +15% vs the market, against −3% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −10.4%, 80% range −15.5% to −2.2%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median

−13.0%

All companies' median

−2.6%

Beat the market

38% vs 47%

50 past situations · 50 companies · 37 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
PATANJALI Process Industries	Feb 2025	—	2%	+15%	−11%	−27%
NH Health Services	Feb 2022	—	2%	+59%	0%	+10%
GMRAIRPORT Transportation	Apr 2023	—	5%	+21%	0%	+26%
BHARATFORG Producer Manufacturing	Jun 2021	—	3%	+139%	0%	−15%
FORTIS Health Services	Feb 2020	—	6%	+14%	−6%	−25%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
STAR Health Technology	Aug 2024	—	7%	+202%	0%	−22%
HCG Health Services	May 2022	—	-1%	+54%	−7%	+3%
BAJAJELEC Consumer Durables	Apr 2021	—	7%	+238%	0%	−23%

How reliable is this?

Matched on P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: interest cover, 12-month momentum and ROCE. Not used (unavailable for this company): P/E. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to PIRAMAL PHARMA LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

BALRAMPUR CHINI MILLSBALRAMCHIN

Process Industries

69%similar

debt/equityrevenue

AARTI INDUSTRIESAARTIIND

Process Industries

63%similar

revenuedebt/equity

THE RAMCO CEMENTSRAMCOCEM

Non-Energy Minerals

57%similar

revenuemarket cap

INTERGLOBE AVIATIONINDIGO

Transportation

56%similar

ROCEpromoter holding

AMBER ENTERPRISES INDIAAMBER

Producer Manufacturing

54%similar

operating marginpromoter holding

JUBILANT PHARMOVAJUBLPHARMA

Health Technology

59%similar

revenuerevenue growth

BIOCONBIOCON

Health Technology

37%similar

ROCEmarket cap

DR REDDYS LABORATORIESDRREDDY

Health Technology

36%similar

revenue growthpromoter holding

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '23

2026
OctPriceVolume reached 41.0x its 50-day median on 2026-10-28; price +17.1% that day.
SepResultsRevenue (TTM) reached a new high of ₹9,205 cr.
SepInstitutionsFII + DII holding fell 18.7 pts over 1 quarter to 27.1%.
SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
JulPriceVolume reached 10.8x its 50-day median on 2026-07-03; price +4.6% that day.
JunPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
JunDividendDividend payout cut from 20% to 0% of profit.
JunPriceVolume reached 34.5x its 50-day median on 2026-06-23; price +6.5% that day.

Show 22 earlier events

2026
AprPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
MarPriceFell 55% from the Nov 2024 peak to the Mar 2026 low.
JanPriceVolume reached 6.5x its 50-day median on 2026-01-29; price -0.2% that day.
2025
DecResultsEPS (TTM) turned negative.
DecPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
NovPriceVolume reached 5.6x its 50-day median on 2025-11-06; price -0.5% that day.
SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 2nd quartile).
SepPriceVolume reached 9.3x its 50-day median on 2025-09-03; price +7.7% that day.
JunPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
JunDividendDividend payout cut from 82% to 20% of profit.
FebPriceVolume reached 15.3x its 50-day median on 2025-02-20; price +9.0% that day.
2024
OctPriceVolume reached 21.2x its 50-day median on 2024-10-24; price +17.4% that day.
SepPriceVolume reached 19.2x its 50-day median on 2024-09-04; price +10.3% that day.
AugPriceRegained the 2022-10 peak, 17 months after the low.
JunResultsEPS (TTM) turned positive.
JunDividendStarted paying a dividend (payout 82% of profit).
JunSharesShare count is up 10.9% over 12 months.
MayPriceVolume reached 15.0x its 50-day median on 2024-05-13; price +2.5% that day.
2023
OctPriceVolume reached 16.5x its 50-day median on 2023-10-31; price +9.5% that day.
JulPriceVolume reached 5.7x its 50-day median on 2023-07-17; price +9.2% that day.
JunDividendDividend payout cut from 18% to 0% of profit.
JunPriceVolume reached 13.6x its 50-day median on 2023-06-16; price +2.7% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history50 months · 2022-10 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	—	₹9205 cr	-3.8%	3.0%	0.7x
2026-10	—	₹9205 cr	-3.8%	3.0%	0.7x
2026-09	—	₹9205 cr	-3.8%	3.0%	0.7x
2026-08	—	₹8869 cr	-4.0%	3.0%	0.7x
2026-07	—	₹8869 cr	-4.0%	3.0%	0.7x
2026-06	—	₹8869 cr	-4.0%	3.0%	0.7x
2026-05	—	₹8871 cr	-2.0%	6.0%	0.6x
2026-04	—	₹8871 cr	-2.0%	6.0%	0.6x
2026-03	—	₹8871 cr	-2.0%	6.0%	0.6x
2026-02	—	₹8936 cr	-0.3%	6.0%	0.6x
2026-01	—	₹8936 cr	-0.3%	6.0%	0.6x
2025-12	—	₹8936 cr	-0.3%	6.0%	0.6x
2025-11	249.6x	₹9134 cr	1.2%	6.0%	0.6x
2025-10	266.2x	₹9134 cr	1.2%	6.0%	0.6x
2025-09	254.9x	₹9134 cr	1.2%	6.0%	0.6x
2025-08	265.9x	₹9151 cr	1.1%	6.0%	0.6x
2025-07	285.6x	₹9151 cr	1.1%	6.0%	0.6x
2025-06	294.8x	₹9151 cr	1.1%	6.0%	0.6x
2025-05	687.7x	₹8949 cr	0.5%	5.0%	0.6x
2025-04	703.5x	₹8949 cr	0.5%	5.0%	0.6x
2025-03	749.2x	₹8949 cr	0.5%	5.0%	0.6x
2025-02	542.5x	₹8704 cr	0.6%	5.0%	0.6x
2025-01	665.4x	₹8704 cr	0.6%	5.0%	0.6x
2024-12	760.7x	₹8704 cr	0.6%	5.0%	0.6x
2024-11	1221.6x	₹8373 cr	0.4%	5.0%	0.6x
2024-10	1220.3x	₹8373 cr	0.4%	5.0%	0.6x
2024-09	1041.0x	₹8373 cr	0.4%	5.0%	0.6x
2024-08	1453.7x	₹8171 cr	0.2%	5.0%	0.6x
2024-07	1354.2x	₹8171 cr	0.2%	5.0%	0.6x
2024-06	1209.5x	₹8171 cr	0.2%	5.0%	0.6x
2024-05	—	₹7082 cr	-2.7%	2.0%	0.8x
2024-04	—	₹7082 cr	-2.7%	2.0%	0.8x
2024-03	—	₹7082 cr	-2.7%	2.0%	0.8x
2024-02	—	₹7082 cr	-2.7%	2.0%	0.8x
2024-01	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-12	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-11	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-10	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-09	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-08	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-07	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-06	—	₹7082 cr	-2.7%	2.0%	0.8x
2023-05	—	₹6559 cr	5.6%	7.0%	0.6x
2023-04	—	₹6559 cr	5.6%	7.0%	0.6x
2023-03	—	₹6559 cr	5.6%	7.0%	0.6x
2023-02	—	₹6559 cr	5.6%	7.0%	0.6x
2023-01	—	₹6559 cr	5.6%	7.0%	0.6x
2022-12	—	₹6559 cr	5.6%	7.0%	0.6x
2022-11	—	₹6559 cr	5.6%	7.0%	0.6x
2022-10	—	₹6559 cr	5.6%	7.0%	0.6x

Methodology and data notes